Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Urinary Bladder Neoplasms | 28 | 2023 | 2196 | 3.810 |
Why?
|
Watchful Waiting | 7 | 2023 | 489 | 2.690 |
Why?
|
Carcinoma, Transitional Cell | 13 | 2023 | 778 | 2.570 |
Why?
|
Prostatic Neoplasms | 31 | 2024 | 10999 | 2.160 |
Why?
|
Kidney Neoplasms | 24 | 2023 | 4189 | 2.010 |
Why?
|
Urogenital Neoplasms | 4 | 2021 | 135 | 1.780 |
Why?
|
Ureteral Neoplasms | 5 | 2023 | 100 | 1.720 |
Why?
|
Cystectomy | 11 | 2023 | 675 | 1.300 |
Why?
|
Prostate | 13 | 2024 | 1743 | 1.290 |
Why?
|
Carcinoma, Renal Cell | 13 | 2023 | 3101 | 1.090 |
Why?
|
Penile Neoplasms | 3 | 2018 | 159 | 0.970 |
Why?
|
Magnetic Resonance Imaging, Interventional | 2 | 2021 | 181 | 0.790 |
Why?
|
Urologic Diseases | 1 | 2023 | 239 | 0.740 |
Why?
|
Ultrasonography, Interventional | 4 | 2021 | 1480 | 0.730 |
Why?
|
Prostatectomy | 8 | 2023 | 1858 | 0.640 |
Why?
|
SEER Program | 3 | 2017 | 1506 | 0.590 |
Why?
|
Testicular Neoplasms | 3 | 2023 | 758 | 0.560 |
Why?
|
Hemangiopericytoma | 1 | 2015 | 77 | 0.510 |
Why?
|
Prostate-Specific Antigen | 8 | 2024 | 2441 | 0.470 |
Why?
|
Biomedical Research | 3 | 2023 | 3301 | 0.430 |
Why?
|
Mitomycin | 5 | 2023 | 259 | 0.420 |
Why?
|
Neoplasm Staging | 9 | 2021 | 10961 | 0.420 |
Why?
|
Penis | 1 | 2011 | 207 | 0.370 |
Why?
|
Nephrectomy | 5 | 2021 | 1033 | 0.370 |
Why?
|
Urology | 2 | 2016 | 377 | 0.360 |
Why?
|
Leiomyosarcoma | 1 | 2014 | 469 | 0.360 |
Why?
|
Cystatin B | 1 | 2009 | 11 | 0.350 |
Why?
|
Magnetic Resonance Imaging | 14 | 2024 | 35326 | 0.350 |
Why?
|
Retrospective Studies | 36 | 2024 | 76631 | 0.350 |
Why?
|
Medical Oncology | 1 | 2021 | 2217 | 0.340 |
Why?
|
Humans | 99 | 2024 | 739398 | 0.340 |
Why?
|
Disease Progression | 6 | 2023 | 13237 | 0.340 |
Why?
|
Lymphatic Metastasis | 3 | 2015 | 2897 | 0.340 |
Why?
|
Forecasting | 2 | 2021 | 2952 | 0.340 |
Why?
|
Male | 68 | 2024 | 349022 | 0.340 |
Why?
|
Congresses as Topic | 1 | 2013 | 760 | 0.340 |
Why?
|
Biopsy | 9 | 2023 | 6722 | 0.290 |
Why?
|
Neoplasm Invasiveness | 9 | 2023 | 3603 | 0.290 |
Why?
|
Hematuria | 2 | 2023 | 234 | 0.290 |
Why?
|
Nanoparticles | 2 | 2009 | 1906 | 0.290 |
Why?
|
Lymph Node Excision | 2 | 2023 | 1242 | 0.290 |
Why?
|
Urination Disorders | 2 | 2016 | 240 | 0.280 |
Why?
|
Urinary Bladder | 4 | 2023 | 1153 | 0.270 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2023 | 9122 | 0.270 |
Why?
|
Stress, Psychological | 1 | 2021 | 4212 | 0.270 |
Why?
|
Carcinoma in Situ | 1 | 2011 | 799 | 0.270 |
Why?
|
Ureteroscopy | 2 | 2023 | 130 | 0.260 |
Why?
|
Cell Proliferation | 5 | 2020 | 10455 | 0.250 |
Why?
|
Urothelium | 3 | 2022 | 277 | 0.250 |
Why?
|
Kaplan-Meier Estimate | 9 | 2021 | 6516 | 0.250 |
Why?
|
Aged | 37 | 2023 | 162698 | 0.240 |
Why?
|
Data Collection | 1 | 2013 | 3341 | 0.240 |
Why?
|
Combined Modality Therapy | 6 | 2021 | 8605 | 0.240 |
Why?
|
Urologic Neoplasms | 2 | 2020 | 307 | 0.240 |
Why?
|
Spermine | 1 | 2023 | 70 | 0.240 |
Why?
|
Angiomyolipoma | 2 | 2016 | 185 | 0.230 |
Why?
|
Diagnostic Imaging | 2 | 2015 | 3497 | 0.230 |
Why?
|
Disease-Free Survival | 9 | 2017 | 6871 | 0.230 |
Why?
|
Histidine | 1 | 2023 | 313 | 0.220 |
Why?
|
Ureter | 2 | 2023 | 361 | 0.220 |
Why?
|
BK Virus | 2 | 2020 | 129 | 0.220 |
Why?
|
Phenylalanine | 1 | 2023 | 365 | 0.210 |
Why?
|
Nephrons | 1 | 2023 | 217 | 0.210 |
Why?
|
Polyomavirus Infections | 2 | 2020 | 196 | 0.200 |
Why?
|
Urinary Diversion | 2 | 2014 | 135 | 0.200 |
Why?
|
Pelvic Neoplasms | 1 | 2023 | 254 | 0.200 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2016 | 1771 | 0.190 |
Why?
|
Tumor Virus Infections | 2 | 2020 | 452 | 0.190 |
Why?
|
Hemofiltration | 1 | 2020 | 57 | 0.190 |
Why?
|
Proportional Hazards Models | 6 | 2017 | 12328 | 0.180 |
Why?
|
Middle Aged | 35 | 2023 | 212863 | 0.180 |
Why?
|
Microphthalmia-Associated Transcription Factor | 1 | 2022 | 251 | 0.180 |
Why?
|
Survival Rate | 6 | 2018 | 12761 | 0.180 |
Why?
|
Organometallic Compounds | 1 | 2023 | 667 | 0.180 |
Why?
|
Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 1 | 2022 | 316 | 0.170 |
Why?
|
Androgen-Insensitivity Syndrome | 1 | 2018 | 31 | 0.170 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2013 | 3908 | 0.170 |
Why?
|
Magnetic Resonance Spectroscopy | 3 | 2023 | 3757 | 0.170 |
Why?
|
Carcinoma, Squamous Cell | 2 | 2011 | 4014 | 0.160 |
Why?
|
Neoplasms, Germ Cell and Embryonal | 1 | 2023 | 480 | 0.160 |
Why?
|
History, 21st Century | 2 | 2021 | 1534 | 0.160 |
Why?
|
Drug Repositioning | 1 | 2020 | 232 | 0.160 |
Why?
|
Urologic Surgical Procedures, Male | 1 | 2018 | 71 | 0.160 |
Why?
|
Cohort Studies | 9 | 2023 | 40389 | 0.160 |
Why?
|
Metabolomics | 2 | 2023 | 1460 | 0.150 |
Why?
|
Melanoma | 1 | 2015 | 5446 | 0.150 |
Why?
|
Muscle Neoplasms | 1 | 2018 | 139 | 0.150 |
Why?
|
Sensitivity and Specificity | 6 | 2023 | 14740 | 0.150 |
Why?
|
Tuberous Sclerosis | 2 | 2016 | 1030 | 0.150 |
Why?
|
Lymph Nodes | 1 | 2009 | 3454 | 0.150 |
Why?
|
Treatment Outcome | 18 | 2023 | 62693 | 0.140 |
Why?
|
Image Enhancement | 1 | 2008 | 2928 | 0.140 |
Why?
|
Office Visits | 1 | 2021 | 600 | 0.140 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 2016 | 60 | 0.140 |
Why?
|
History, 20th Century | 2 | 2021 | 2742 | 0.140 |
Why?
|
Skin Neoplasms | 1 | 2015 | 5632 | 0.140 |
Why?
|
Acrylic Resins | 1 | 2016 | 142 | 0.140 |
Why?
|
Adenoma, Oxyphilic | 1 | 2017 | 136 | 0.140 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2018 | 358 | 0.140 |
Why?
|
Tumor Suppressor Protein p53 | 2 | 2018 | 2948 | 0.130 |
Why?
|
Prognosis | 9 | 2021 | 28901 | 0.130 |
Why?
|
Time Factors | 9 | 2021 | 40050 | 0.130 |
Why?
|
Phthalazines | 1 | 2018 | 357 | 0.130 |
Why?
|
Embolization, Therapeutic | 2 | 2016 | 1376 | 0.130 |
Why?
|
Constriction, Pathologic | 3 | 2023 | 1096 | 0.130 |
Why?
|
Dansyl Compounds | 1 | 2014 | 20 | 0.130 |
Why?
|
Contrast Media | 4 | 2023 | 5293 | 0.130 |
Why?
|
Carcinoma | 2 | 2017 | 2361 | 0.130 |
Why?
|
Statistics, Nonparametric | 2 | 2017 | 2881 | 0.130 |
Why?
|
Health Care Costs | 2 | 2020 | 3226 | 0.130 |
Why?
|
Gelatin | 1 | 2016 | 226 | 0.120 |
Why?
|
United States | 12 | 2024 | 69573 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 6 | 2017 | 20055 | 0.120 |
Why?
|
Urinary Fistula | 1 | 2014 | 40 | 0.120 |
Why?
|
Ablation Techniques | 1 | 2017 | 249 | 0.120 |
Why?
|
Urinary Reservoirs, Continent | 1 | 2014 | 29 | 0.120 |
Why?
|
Uterus | 1 | 2018 | 712 | 0.120 |
Why?
|
Urogenital Surgical Procedures | 1 | 2014 | 35 | 0.120 |
Why?
|
Salvage Therapy | 2 | 2021 | 1269 | 0.120 |
Why?
|
Follow-Up Studies | 8 | 2019 | 38942 | 0.120 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2022 | 1574 | 0.120 |
Why?
|
Intestinal Fistula | 1 | 2014 | 140 | 0.110 |
Why?
|
Laparoscopy | 2 | 2015 | 2091 | 0.110 |
Why?
|
Ureteral Obstruction | 1 | 2015 | 282 | 0.110 |
Why?
|
Survivors | 3 | 2023 | 2280 | 0.110 |
Why?
|
Antigens, CD34 | 1 | 2015 | 656 | 0.110 |
Why?
|
Infertility, Female | 1 | 2018 | 784 | 0.100 |
Why?
|
JNK Mitogen-Activated Protein Kinases | 1 | 2014 | 452 | 0.100 |
Why?
|
Renal Insufficiency, Chronic | 2 | 2023 | 2216 | 0.100 |
Why?
|
Morbidity | 1 | 2017 | 1763 | 0.100 |
Why?
|
Lactones | 1 | 2014 | 329 | 0.100 |
Why?
|
Risk Assessment | 3 | 2022 | 23294 | 0.100 |
Why?
|
Social Support | 1 | 2021 | 2112 | 0.100 |
Why?
|
Female | 29 | 2023 | 378853 | 0.100 |
Why?
|
Chemotherapy, Adjuvant | 3 | 2023 | 3453 | 0.100 |
Why?
|
Aged, 80 and over | 10 | 2021 | 57650 | 0.100 |
Why?
|
Predictive Value of Tests | 5 | 2020 | 15036 | 0.100 |
Why?
|
p38 Mitogen-Activated Protein Kinases | 1 | 2014 | 691 | 0.100 |
Why?
|
Survival Analysis | 3 | 2021 | 10247 | 0.100 |
Why?
|
Genomics | 2 | 2023 | 5652 | 0.100 |
Why?
|
BCG Vaccine | 2 | 2023 | 362 | 0.090 |
Why?
|
Multifactorial Inheritance | 1 | 2017 | 1174 | 0.090 |
Why?
|
Reactive Oxygen Species | 1 | 2018 | 2084 | 0.090 |
Why?
|
Length of Stay | 2 | 2020 | 6295 | 0.090 |
Why?
|
Adenine | 1 | 2014 | 940 | 0.090 |
Why?
|
Surgery, Computer-Assisted | 1 | 2017 | 1008 | 0.080 |
Why?
|
Cystoscopy | 1 | 2009 | 130 | 0.080 |
Why?
|
Dementia | 1 | 2023 | 2488 | 0.080 |
Why?
|
Reoperation | 2 | 2016 | 4192 | 0.080 |
Why?
|
Kidney Pelvis | 2 | 2023 | 174 | 0.080 |
Why?
|
Paroxetine | 1 | 2009 | 182 | 0.080 |
Why?
|
Adult | 18 | 2023 | 213394 | 0.080 |
Why?
|
Education, Medical, Continuing | 1 | 2013 | 840 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2021 | 3514 | 0.080 |
Why?
|
Apoptosis | 2 | 2014 | 9714 | 0.080 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2020 | 3571 | 0.080 |
Why?
|
Quality of Life | 3 | 2018 | 12640 | 0.080 |
Why?
|
Cell Cycle | 4 | 2020 | 2960 | 0.080 |
Why?
|
Case-Control Studies | 2 | 2023 | 21694 | 0.080 |
Why?
|
Neoplasms, Second Primary | 1 | 2015 | 1045 | 0.080 |
Why?
|
Adjuvants, Immunologic | 2 | 2023 | 995 | 0.080 |
Why?
|
Actins | 1 | 2015 | 2112 | 0.080 |
Why?
|
Piperazines | 1 | 2018 | 2480 | 0.080 |
Why?
|
Protein Array Analysis | 1 | 2009 | 411 | 0.070 |
Why?
|
Hospital Mortality | 1 | 2020 | 5305 | 0.070 |
Why?
|
Reproducibility of Results | 4 | 2019 | 19811 | 0.070 |
Why?
|
Autophagy | 1 | 2014 | 1295 | 0.070 |
Why?
|
Enuresis | 1 | 2006 | 47 | 0.070 |
Why?
|
Logistic Models | 1 | 2021 | 13402 | 0.070 |
Why?
|
Ureteral Calculi | 1 | 2007 | 108 | 0.070 |
Why?
|
Neoplastic Stem Cells | 1 | 2014 | 1380 | 0.070 |
Why?
|
Urinary Incontinence, Urge | 1 | 2006 | 45 | 0.070 |
Why?
|
Anemia | 1 | 2015 | 1498 | 0.070 |
Why?
|
Diagnosis, Differential | 4 | 2018 | 12948 | 0.070 |
Why?
|
Biofeedback, Psychology | 1 | 2006 | 115 | 0.070 |
Why?
|
Molecular Biology | 1 | 2009 | 594 | 0.060 |
Why?
|
Proto-Oncogene Proteins B-raf | 1 | 2015 | 2015 | 0.060 |
Why?
|
Muscles | 2 | 2023 | 1608 | 0.060 |
Why?
|
Spermatozoa | 1 | 2009 | 627 | 0.060 |
Why?
|
Multivariate Analysis | 5 | 2017 | 12237 | 0.060 |
Why?
|
Urination | 1 | 2006 | 201 | 0.060 |
Why?
|
Age Factors | 2 | 2019 | 18349 | 0.060 |
Why?
|
Costs and Cost Analysis | 1 | 2010 | 1675 | 0.060 |
Why?
|
Urinary Bladder, Overactive | 1 | 2006 | 104 | 0.060 |
Why?
|
Urodynamics | 1 | 2006 | 342 | 0.060 |
Why?
|
Microscopy, Electron | 1 | 2008 | 2665 | 0.060 |
Why?
|
Learning | 1 | 2013 | 1695 | 0.060 |
Why?
|
Mitomycins | 1 | 2023 | 47 | 0.060 |
Why?
|
Urethra | 1 | 2006 | 401 | 0.060 |
Why?
|
Tumor Burden | 3 | 2016 | 1904 | 0.060 |
Why?
|
Xeroderma Pigmentosum Group D Protein | 1 | 2023 | 103 | 0.060 |
Why?
|
Prospective Studies | 6 | 2024 | 53037 | 0.060 |
Why?
|
Lung Diseases | 1 | 2014 | 1879 | 0.060 |
Why?
|
Administration, Intravesical | 1 | 2023 | 88 | 0.060 |
Why?
|
Propensity Score | 2 | 2023 | 1749 | 0.060 |
Why?
|
Retroperitoneal Space | 1 | 2023 | 171 | 0.060 |
Why?
|
Risk Factors | 8 | 2023 | 71974 | 0.060 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2006 | 385 | 0.050 |
Why?
|
Incidence | 3 | 2017 | 20913 | 0.050 |
Why?
|
Postoperative Complications | 2 | 2023 | 15194 | 0.050 |
Why?
|
Protein Kinases | 1 | 2009 | 1637 | 0.050 |
Why?
|
Ultrasonography | 1 | 2015 | 5941 | 0.050 |
Why?
|
Mass Spectrometry | 1 | 2009 | 2200 | 0.050 |
Why?
|
Young Adult | 7 | 2020 | 56255 | 0.050 |
Why?
|
Urinary Incontinence | 1 | 2006 | 490 | 0.050 |
Why?
|
Societies, Medical | 1 | 2013 | 3739 | 0.050 |
Why?
|
Early Detection of Cancer | 1 | 2015 | 3051 | 0.050 |
Why?
|
Pandemics | 1 | 2021 | 8274 | 0.050 |
Why?
|
Transplantation, Homologous | 2 | 2020 | 4768 | 0.050 |
Why?
|
Neoplasm Metastasis | 2 | 2008 | 4832 | 0.050 |
Why?
|
Peritoneum | 1 | 2021 | 226 | 0.050 |
Why?
|
Perineum | 1 | 2021 | 211 | 0.050 |
Why?
|
Gadolinium DTPA | 1 | 2023 | 836 | 0.050 |
Why?
|
Incidental Findings | 2 | 2018 | 690 | 0.050 |
Why?
|
Physical Examination | 1 | 2006 | 1231 | 0.040 |
Why?
|
Patient Selection | 3 | 2018 | 4211 | 0.040 |
Why?
|
Tissue Distribution | 1 | 2023 | 2345 | 0.040 |
Why?
|
Positron-Emission Tomography | 1 | 2015 | 6361 | 0.040 |
Why?
|
Boston | 3 | 2017 | 9314 | 0.040 |
Why?
|
Catheter Ablation | 1 | 2012 | 2737 | 0.040 |
Why?
|
Practice Guidelines as Topic | 1 | 2016 | 7274 | 0.040 |
Why?
|
Gene Fusion | 1 | 2022 | 371 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2020 | 3922 | 0.040 |
Why?
|
46, XX Disorders of Sex Development | 1 | 2018 | 31 | 0.040 |
Why?
|
Vascular Endothelial Growth Factor Receptor-1 | 1 | 2022 | 551 | 0.040 |
Why?
|
Collagen | 1 | 2007 | 2671 | 0.040 |
Why?
|
Virus Integration | 1 | 2020 | 297 | 0.040 |
Why?
|
Gadolinium | 1 | 2023 | 951 | 0.040 |
Why?
|
Neoadjuvant Therapy | 1 | 2009 | 2688 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2023 | 1583 | 0.040 |
Why?
|
Child, Preschool | 2 | 2014 | 40802 | 0.040 |
Why?
|
Mullerian Ducts | 1 | 2018 | 198 | 0.040 |
Why?
|
Cisplatin | 1 | 2023 | 1617 | 0.040 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2020 | 740 | 0.040 |
Why?
|
Computational Biology | 1 | 2009 | 3506 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13635 | 0.040 |
Why?
|
Recurrence | 1 | 2009 | 8307 | 0.040 |
Why?
|
Adolescent | 5 | 2020 | 85405 | 0.040 |
Why?
|
Child | 4 | 2016 | 77033 | 0.040 |
Why?
|
Heart Failure | 1 | 2020 | 10793 | 0.040 |
Why?
|
Blotting, Western | 2 | 2014 | 5181 | 0.040 |
Why?
|
Kidney | 2 | 2023 | 7144 | 0.040 |
Why?
|
Signal Transduction | 3 | 2014 | 23355 | 0.040 |
Why?
|
Tumor Cells, Cultured | 2 | 2014 | 6310 | 0.030 |
Why?
|
Ultrasonography, Doppler | 1 | 2018 | 460 | 0.030 |
Why?
|
Leukocyte Disorders | 1 | 2015 | 12 | 0.030 |
Why?
|
Income | 1 | 2024 | 1877 | 0.030 |
Why?
|
Language | 1 | 2024 | 1447 | 0.030 |
Why?
|
Poland | 1 | 2014 | 184 | 0.030 |
Why?
|
Congenital Abnormalities | 1 | 2018 | 708 | 0.030 |
Why?
|
DNA Breaks, Double-Stranded | 1 | 2018 | 588 | 0.030 |
Why?
|
Comparative Effectiveness Research | 1 | 2018 | 679 | 0.030 |
Why?
|
Comorbidity | 2 | 2020 | 10362 | 0.030 |
Why?
|
Sexual Dysfunction, Physiological | 1 | 2016 | 357 | 0.030 |
Why?
|
Odds Ratio | 2 | 2016 | 9846 | 0.030 |
Why?
|
Preoperative Period | 1 | 2015 | 546 | 0.030 |
Why?
|
Evidence-Based Medicine | 2 | 2016 | 3606 | 0.030 |
Why?
|
Cell Line, Tumor | 2 | 2020 | 16646 | 0.030 |
Why?
|
Hospitals, General | 1 | 2017 | 744 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2012 | 6370 | 0.030 |
Why?
|
Heterocyclic Compounds, 3-Ring | 1 | 2014 | 217 | 0.030 |
Why?
|
Particle Size | 1 | 2016 | 1639 | 0.030 |
Why?
|
Area Under Curve | 1 | 2016 | 1655 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2018 | 10945 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2009 | 6318 | 0.030 |
Why?
|
Leukocyte Count | 1 | 2015 | 1581 | 0.020 |
Why?
|
Intestinal Diseases | 1 | 2016 | 531 | 0.020 |
Why?
|
Digital Rectal Examination | 1 | 2010 | 42 | 0.020 |
Why?
|
Internationality | 1 | 2016 | 1004 | 0.020 |
Why?
|
Health Expenditures | 1 | 2023 | 2348 | 0.020 |
Why?
|
Acute Disease | 1 | 2020 | 7128 | 0.020 |
Why?
|
Radiation Oncology | 1 | 2016 | 553 | 0.020 |
Why?
|
Quality Improvement | 2 | 2015 | 3730 | 0.020 |
Why?
|
Databases, Factual | 2 | 2015 | 7690 | 0.020 |
Why?
|
Radiotherapy Dosage | 1 | 2016 | 2872 | 0.020 |
Why?
|
Cyclin B | 1 | 2009 | 108 | 0.020 |
Why?
|
Aorta | 1 | 2017 | 2048 | 0.020 |
Why?
|
Radiographic Image Enhancement | 1 | 2014 | 884 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2021 | 3280 | 0.020 |
Why?
|
DNA Fragmentation | 1 | 2009 | 241 | 0.020 |
Why?
|
CDC2 Protein Kinase | 1 | 2009 | 220 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2015 | 1296 | 0.020 |
Why?
|
Tetradecanoylphorbol Acetate | 1 | 2009 | 821 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2009 | 11410 | 0.020 |
Why?
|
ROC Curve | 1 | 2016 | 3526 | 0.020 |
Why?
|
Anticoagulants | 1 | 2023 | 4582 | 0.020 |
Why?
|
China | 1 | 2014 | 2225 | 0.020 |
Why?
|
Drainage | 1 | 2014 | 1139 | 0.020 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2022 | 4424 | 0.020 |
Why?
|
Cell Shape | 1 | 2009 | 375 | 0.020 |
Why?
|
In Situ Hybridization, Fluorescence | 1 | 2014 | 2634 | 0.020 |
Why?
|
Cell Survival | 1 | 2018 | 5877 | 0.020 |
Why?
|
Semen Analysis | 1 | 2009 | 204 | 0.020 |
Why?
|
Lymphocytes | 1 | 2015 | 2612 | 0.020 |
Why?
|
Immunohistochemistry | 2 | 2014 | 11347 | 0.020 |
Why?
|
Proteomics | 1 | 2020 | 3584 | 0.020 |
Why?
|
Rats | 1 | 2023 | 24270 | 0.020 |
Why?
|
Markov Chains | 1 | 2010 | 970 | 0.020 |
Why?
|
Terminology as Topic | 1 | 2014 | 1548 | 0.020 |
Why?
|
Epidermal Growth Factor | 1 | 2009 | 706 | 0.020 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2014 | 4743 | 0.020 |
Why?
|
Preoperative Care | 1 | 2015 | 2238 | 0.020 |
Why?
|
Cyclin-Dependent Kinases | 1 | 2009 | 670 | 0.020 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2009 | 503 | 0.020 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2022 | 8400 | 0.020 |
Why?
|
Protein Kinase Inhibitors | 1 | 2022 | 5502 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 1364 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2020 | 4220 | 0.020 |
Why?
|
Neoplasms | 1 | 2014 | 21507 | 0.020 |
Why?
|
Pilot Projects | 1 | 2018 | 8275 | 0.020 |
Why?
|
Treatment Failure | 1 | 2011 | 2614 | 0.020 |
Why?
|
Mitochondria | 1 | 2018 | 3522 | 0.020 |
Why?
|
Urologic Surgical Procedures | 1 | 2007 | 277 | 0.020 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1689 | 0.010 |
Why?
|
Flow Cytometry | 1 | 2014 | 5959 | 0.010 |
Why?
|
Life Expectancy | 1 | 2010 | 1208 | 0.010 |
Why?
|
HeLa Cells | 1 | 2009 | 3119 | 0.010 |
Why?
|
Neutrophils | 1 | 2015 | 3698 | 0.010 |
Why?
|
Cluster Analysis | 1 | 2009 | 2711 | 0.010 |
Why?
|
Diabetes Mellitus | 1 | 2020 | 5702 | 0.010 |
Why?
|
Mutation | 2 | 2018 | 29658 | 0.010 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2009 | 1659 | 0.010 |
Why?
|
Hospitalization | 1 | 2020 | 10208 | 0.010 |
Why?
|
Algorithms | 1 | 2021 | 13872 | 0.010 |
Why?
|
Proto-Oncogene Proteins c-akt | 1 | 2009 | 2507 | 0.010 |
Why?
|
Hypertension | 1 | 2020 | 8431 | 0.010 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2016 | 9812 | 0.010 |
Why?
|
Antibodies | 1 | 2007 | 2450 | 0.010 |
Why?
|
RNA, Messenger | 1 | 2014 | 13002 | 0.010 |
Why?
|
Equipment Design | 1 | 2007 | 3583 | 0.010 |
Why?
|
Phosphorylation | 1 | 2009 | 8416 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2014 | 9387 | 0.010 |
Why?
|
Up-Regulation | 1 | 2007 | 4205 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2010 | 5462 | 0.010 |
Why?
|
Brain | 1 | 2023 | 26345 | 0.010 |
Why?
|
Decision Making | 1 | 2010 | 3854 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2016 | 24714 | 0.010 |
Why?
|
Insulin | 1 | 2009 | 6569 | 0.010 |
Why?
|
Cells, Cultured | 1 | 2009 | 19220 | 0.010 |
Why?
|
Animals | 1 | 2023 | 168368 | 0.010 |
Why?
|